Literature DB >> 30390352

Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease.

Hongmei Zhang1, Yixin Niu1, Hongxia Gu1, Shuai Lu1, Weiwei Zhang1, Xiaoyong Li1, Zhen Yang1, Li Qin1, Qing Su1.   

Abstract

BACKGROUND: The association between adiponectin and nonalcoholic fatty liver disease (NAFLD) has been studied before, but most of the studies are cross-sectional and cannot prove a causal link.
OBJECTIVE: To prospectively investigate the relationship between serum adiponectin levels and the incidence of NAFLD in 3 years. SUBJECTS AND METHODS: A total of 1325 subjects aged 40 to 70 from the Chongming District of Shanghai, China, were included. All of them did not have fatty liver according to the liver ultrasound examination at entry; alcohol abuse and hepatitis were also excluded. Serum adiponectin levels and other indices were measured at baseline. After 3 years of follow-up, hepatic ultrasound examination was performed on each participant again to detect fatty liver.
RESULTS: The serum adiponectin levels at entry were significantly lower in subjects who developed NAFLD compared with those who did not develop NAFLD after 3 years (1.75 ± 0.89 ug/mL vs 2.37 ± 1.01 ug/mL, P < 0.001). After multiple adjustments, the highest odds ratios for NAFLD were in the second adiponectin quartile, the adjusted ORs were 1.89 (95% confidence interval [CI] 1.25 to 2.86) compared with those in the highest quartile. Multivariate logistic regression analysis showing variables at entry independently associated with NAFLD after 3 years was adiponectin (P < 0.01), sex (P < 0.01), BMI (P < 0.001), insulin (P < 0.001), HOMA-IR (P < 0.01), GGT (P = 0.001), TG (P < 0.001), and WBC (P < 0.001).
CONCLUSIONS: Lower serum adiponectin level is a predictor of NAFLD among middle-aged and elderly subjects.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Adiponectin; NAFLD; insulin resistance; prospective

Mesh:

Substances:

Year:  2018        PMID: 30390352      PMCID: PMC6818611          DOI: 10.1002/jcla.22709

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  34 in total

1.  Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.

Authors:  Raj Vuppalanchi; Smitha Marri; Dhanashri Kolwankar; Robert V Considine; Naga Chalasani
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

2.  Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome.

Authors:  K M Choi; O H Ryu; K W Lee; H Y Kim; J A Seo; S G Kim; N H Kim; D S Choi; S H Baik
Journal:  Diabetes Res Clin Pract       Date:  2006-07-26       Impact factor: 5.602

3.  Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis.

Authors:  Giovanni Musso; Roberto Gambino; Giampaolo Biroli; Monica Carello; Emanuela Fagà; Giovanni Pacini; Franco De Michieli; Maurizio Cassader; Marilena Durazzo; Mario Rizzetto; Gianfranco Pagano
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

4.  World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Douglas R LaBrecque; Zaigham Abbas; Frank Anania; Peter Ferenci; Aamir G Khan; Khean-Lee Goh; Saeed S Hamid; Vasily Isakov; Maribel Lizarzabal; Manuel M Peñaranda; Juan F R Ramos; Shiv Sarin; Davor Stimac; Alan B R Thomson; Muhammed Umar; Justus Krabshuis; Anton LeMair
Journal:  J Clin Gastroenterol       Date:  2014-07       Impact factor: 3.062

Review 5.  Adiponectin: key player in the adipose tissue-liver crosstalk.

Authors:  A R Moschen; V Wieser; H Tilg
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 6.  Non-alcoholic fatty liver disease: an overview.

Authors:  Brian P Mulhall; Janus P Ong; Zobair M Younossi
Journal:  J Gastroenterol Hepatol       Date:  2002-11       Impact factor: 4.029

7.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

8.  Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.

Authors:  Xiaona Hu; Yiqin Huang; Zhijun Bao; Yiqian Wang; Dongmei Shi; Fang Liu; Zhanjuan Gao; Xiaofeng Yu
Journal:  BMC Gastroenterol       Date:  2012-09-14       Impact factor: 3.067

Review 9.  Diagnosis and evaluation of nonalcoholic fatty liver disease.

Authors:  Mikako Obika; Hirofumi Noguchi
Journal:  Exp Diabetes Res       Date:  2011-10-27

Review 10.  Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions.

Authors:  Timon E Adolph; Christoph Grander; Felix Grabherr; Herbert Tilg
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

View more
  7 in total

1.  Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease.

Authors:  Hongmei Zhang; Yixin Niu; Hongxia Gu; Shuai Lu; Weiwei Zhang; Xiaoyong Li; Zhen Yang; Li Qin; Qing Su
Journal:  J Clin Lab Anal       Date:  2018-11-02       Impact factor: 2.352

Review 2.  Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents.

Authors:  Farah D R Al-Baiaty; Aziana Ismail; Zarina Abdul Latiff; Khairul Najmi Muhammad Nawawi; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar
Journal:  Front Pediatr       Date:  2021-07-08       Impact factor: 3.418

3.  Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study.

Authors:  Nengguang Fan; Liang Peng; Zhenhua Xia; Lijuan Zhang; Zhiyi Song; Yufan Wang; Yongde Peng
Journal:  Lipids Health Dis       Date:  2019-02-02       Impact factor: 3.876

4.  Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity.

Authors:  Emir Tas; Shasha Bai; Xiawei Ou; Kelly Mercer; Haixia Lin; Kori Mansfield; Robert Buchmann; Eva C Diaz; Jon Oden; Elisabet Børsheim; Sean H Adams; Jonathan Dranoff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-17       Impact factor: 5.555

5.  Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

Authors:  Rasha R El-Kady; Amani K Ali; Lamia M El Wakeel; Nagwa A Sabri; May A Shawki
Journal:  Ther Adv Chronic Dis       Date:  2022-02-23       Impact factor: 5.091

6.  Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn's Disease.

Authors:  Zhou Zhou; Yinghui Zhang; Xue Yang; Yan Pan; Liangping Li; Caiping Gao; Chong He
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

Review 7.  NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.

Authors:  Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico
Journal:  Int J Environ Res Public Health       Date:  2019-09-14       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.